Search - tctmd.com

Displaying 481 - 500 of 754

Sort: Relevancy | Date

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

September 01, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

ESC Updates Guidelines for Treating STEMI Patients

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

News Daily News

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

July 20, 2017

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

News Daily News

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

June 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.